Gene-modified cell therapy (GMCT) represents the most effective platform for many patients with advanced disease. These therapies, however, are held back by inefficient development processes and manufacturing scales that are limited to a minute fraction of the relevant patient populations due to current gene delivery methods such as viral vectors. Simulation is helping to accelerate this development process and advance cell therapy.
Indee Labs is a Y Combinator company spun out of the Australian National Fabrication Facility. The team is developing novel gene delivery technology that uses ANSYS computational fluid dynamics solutions to gently and efficiently deliver genetic materials such as CRISPR to your immune cells. Indee Labs views gene delivery as the most problematic step in developing and manufacturing GMCTs since a global shortage in viral vectors has led Big Pharma to invest hundreds of millions of dollars into their own manufacturing facilities. Continue reading